In fact, the SiRe® panel has previously been designed and validated for both tissue samples and liquid biopsy specimens to cover 568 clinically relevant mutations in six genes (EGFR, KRAS, NRAS, BRAF, cKIT, and PDGFRα) involved in NSCLC, gastrointestinal stromal tumor, mCRC, and melanoma, meeting the clinical indication for drug prescription from the European Medical Agency. This evidence concerns the gene BRAF and gastrointestinal stromal tumor.